← Leaderboards
Abhay R. Satoskar
Ohio State University
$6,958,835
Attributed
$9,528,646
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,528,646 · 14
By mechanism
RC4$2,626,966 · 1
R21$2,028,494 · 5
U01$1,736,288 · 1
R56$1,403,969 · 2
R01$953,941 · 1
R03$550,238 · 3
Top collaborators
- Damaris Matoke7 shared
- Michael Ibba2 shared
- Elyes Zhioua2 shared
- Alan Douglas Kinghorn1 shared
Others in their field
Top investigators on “Leishmaniasis”
- Wilhelmus G. J. Hol · University Of Washington$31,003,173
- Phillip A. Scott · University Of Pennsylvania$23,688,775
- Stephen M Beverley · Washington University$22,938,258
- Mary Edythe Wilson · University Of Iowa$10,364,568
- Diane McMahon Pratt · Yale University$7,903,133
- William H Gerwick · Oregon State University$7,792,712
Research focus
LeishmaniasisParasitesInfectionVisceral LeishmaniasisGlobal HealthSiteLesionCellsChronicImmuneLifeAnimalsHealingMacrophageVectorFoundationsCutaneousSkinNeglected Tropical DiseasesGenesSourceLeishmania DonovaniMutationLeishmania (Genus)
Grant awards (32)
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$210,577
U01 · FY2025 · AI · contact PI
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$86,975
U01 · FY2025 · AI · contact PI
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$72,923
U01 · FY2025 · AI · contact PI
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$60,763
U01 · FY2025 · AI · contact PI
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$433,155
U01 · FY2024 · AI · contact PI
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$435,030
U01 · FY2023 · AI · contact PI
A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa$436,865
U01 · FY2022 · AI · contact PI
Development of a live attenuated vaccine for visceral leishmaniasis$78,000
R03 · FY2021 · AI · contact PI
Development of a live attenuated vaccine for visceral leishmaniasis$78,000
R03 · FY2020 · AI · contact PI
Characterization of bystander immunosuppression during visceral leishmaniasis$195,000
R21 · FY2019 · AI · contact PI
A live attenuated vaccine for leishmaniasis$166,973
R21 · FY2019 · AI · contact PI
Characterization of bystander immunosuppression during visceral leishmaniasis$234,000
R21 · FY2018 · AI · contact PI
A live attenuated vaccine for leishmaniasis$208,827
R21 · FY2018 · AI · contact PI
A Systems Biology Approach for Targeted Drug Discovery for Leishmaniasis$205,141
R21 · FY2018 · AI
A Systems Biology Approach for Targeted Drug Discovery for Leishmaniasis$195,428
R21 · FY2017 · AI
Chemopreventition and treatment of non-melanoma skin cancer by targeting MIF$76,250
R03 · FY2013 · CA · contact PI
Treating cutaneous leishmaniasis by radio-frequency induced heat (RFH) therapy$228,750
R34 · FY2012 · AI · contact PI
Chemopreventition and treatment of non-melanoma skin cancer by targeting MIF$76,250
R03 · FY2012 · CA · contact PI
Visualization of CXCR3 allelic usage in vivo$165,488
R03 · FY2011 · AI · contact PI
Development of novel therapeutics for a neglected tropical disease leishmaniasis$2,626,966
RC4 · FY2010 · AI · contact PI
Discovery of novel antileishmanial molecules from the plant Pentalinon andreuxii$803,969
R56 · FY2010 · AI · contact PI
Treatment of cutaneous leishmaniasis using Pentalinon andrieuxii root extract$185,625
R21 · FY2010 · AT · contact PI
Visualization of CXCR3 allelic usage in vivo$76,250
R03 · FY2010 · AI · contact PI
Chemokines and regulation of T cell responses during infection$300,000
R56 · FY2009 · AI · contact PI
Treatment of cutaneous leishmaniasis using Pentalinon andrieuxii root extract$225,000
R21 · FY2009 · AT · contact PI
Isolation of novel antileishmanial molecules from Pentalinon andrieuxii root$187,500
R21 · FY2009 · AI · contact PI
Chemokines and regulation of T cell responses during infection$300,000
R56 · FY2008 · AI · contact PI
Isolation of novel antileishmanial molecules from Pentalinon andrieuxii root$225,000
R21 · FY2008 · AI · contact PI
Mechanisms of sex-determined resistance to L. mexicana$221,251
R01 · FY2005 · AI
Mechanisms of sex-determined resistance to L. mexicana$221,251
R01 · FY2004 · AI
Mechanisms of sex-determined resistance to L. mexicana$221,251
R01 · FY2003 · AI
Mechanisms of sex-determined resistance to L. mexicana$290,188
R01 · FY2002 · AI